US Patent 8410047 Counteracting drug-induced obesity using GLP-1 agonists
Patent 8410047 was granted and assigned to Novo Nordisk on April, 2013 by the United States Patent and Trademark Office.
All edits
Edits on 17 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 29 Nov, 2023
Golden AI
Edits made to:
Article (+151 characters)
Article
Patent abstract
The present invention describes administering a GLP-1 agonist to treat obesity caused by the administration of an obesity-inducing drug.
Edits on 18 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08410047 Counteracting drug-induced obesity using GLP-1 agonists US Patent 8410047 Counteracting drug-induced obesity using GLP-1 agonists
Infobox
Patent Number
0841004700
Patent Number
841004700
Edits on 25 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
084100470
Date of Patent
April 2, 2013
0Patent Application Number
116292380
Date Filed
May 31, 2005
0Patent Primary Examiner
Edits on 28 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
084100470
Date of Patent
April 2, 2013
0Patent Application Number
116292380
Date Filed
May 31, 2005
0Patent Primary Examiner
Edits on 16 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08410047 Counteracting drug-induced obesity using GLP-1 agonists
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08410047
Date of patent
April 2, 2013
Patent application number
11629238
Date Filed
May 31, 2005
Patent primary examiner
Find more entities like US Patent 8410047 Counteracting drug-induced obesity using GLP-1 agonists
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
